Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets The agreement - OBT's second high-profile ...

With the rise of targeted protein degraders over the past decade, early adopters promised that these small molecules would be able to unlock previously intractable targets. A first wave of molecular ...

Multiple myeloma is an incurable plasma cell malignancy despite major therapeutic advances. A recent review by Chinese ...

The discovery of a novel target can result in exceptionally successful classes of anticancer drugs. For example, the combined global sales in 2024 of PD1–PDL1 inhibitors — for which the first-in-class ...

Studies by an international team of researchers headed by investigators in the labs of Margaret Goodell, PhD, and Joshua Riback, PhD, at Baylor College of Medicine, suggest that a hidden structure ...

People who experience an arterial ischemic stroke (AIS) or transient ischemic stroke (TIA) are at an increased risk of suffering a second stroke or other major adverse cardiovascular event (MACE), ...

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions. This collaboration ...

THRAP3, STMN1, and GNA13 are overexpressed in blood cancers, correlating with poor prognosis and shorter survival. THRAP3 is linked to cancer proliferation and survival pathways, suggesting its ...

BOSTON & NEW HAVEN, Conn.--(BUSINESS WIRE)--Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The ...